Suscribirse

The Relationship Between Serum 25(OH)D and Parathyroid Hormone Levels - 24/11/11

Doi : 10.1016/j.amjmed.2011.07.009 
Walid Saliba, MD, MPH a, , Ofra Barnett, PhD a, Hedy S. Rennert, MPH a, Idit Lavi, MA a, Gad Rennert, MD, PhD a, b
a Department of Community Medicine and Epidemiology, Carmel Medical Center, Clalit Health Services, and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel 
b Department of Epidemiology and Disease Prevention, Office of the Chief Physician, Clalit Health Services Headquarters, Tel Aviv, Israel 

Requests for reprints should be addressed to Walid Saliba, MD, MPH, Department of Community Medicine and Epidemiology, Carmel Medical Center, 7 Michal St, Haifa 34362, Israel

Abstract

Objective

Low 25(OH)D levels are associated with increased parathyroid hormone levels leading to progressive bone loss. The serum levels of 25(OH)D sufficient to keep the parathyroid hormone level at a range that will prevent bone loss are still unclear. The current study was aimed at evaluating the relationship between 25(OH)D levels and concomitant parathyroid hormone levels.

Methods

The computerized laboratory database of Clalit Health Services, a not-for-profit health maintenance organization covering more than half of the Israeli population, was searched for all 25(OH)D and parathyroid hormone tests performed in 2009. Concomitant tests of parathyroid hormone and 25(OH)D were identified in 19,172 people.

Results

Serum parathyroid hormone levels were inversely correlated with 25(OH)D levels (r = −0.176, P < .001); 25(OH)D levels less than 50 nmol/L were associated with a steep increase in parathyroid hormone levels and hyperparathyroidism, which decreased with increasing 25(OH)D levels and reached a plateau at 25(OH)D levels of 75 to 85 nmol/L. The quadratic fit with plateau model showed that parathyroid hormone stabilizes at 25(OH)D level of 78.9 nmol/L. However, after excluding 5449 people with hypercalcemia or renal failure, the parathyroid hormone plateau was attained at a significantly lower 25(OH)D cut point of 46.2 nmol/L.

Conclusion

Our data suggest that a 25(OH)D threshold of 50 nmol/L is sufficient for parathyroid hormone suppression and prevention of secondary hyperparathyroidism in persons with normal renal function. 25(OH)D levels greater than 75 nmol/L do not seem to be associated with additional change in parathyroid hormone levels.

El texto completo de este artículo está disponible en PDF.

Esquema


 Funding: None.
 Conflict of Interest: None of the authors have any conflicts of interest associated with the work presented in this manuscript.
 Authorship: All authors had access to the data and played a role in writing this manuscript.


© 2011  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 124 - N° 12

P. 1165-1170 - décembre 2011 Regresar al número
Artículo precedente Artículo precedente
  • Pyogenic Liver Abscess as the Initial Manifestation of Underlying Hepatocellular Carcinoma
  • Yi-Tsung Lin, Chia-Jen Liu, Tzeng-Ji Chen, Te-Li Chen, Yi-Chen Yeh, Hau-Shin Wu, Chih-Peng Tseng, Fu-Der Wang, Cheng-Hwai Tzeng, Chang-Phone Fung
| Artículo siguiente Artículo siguiente
  • Endothelial Dysfunction Is Reversible in Helicobacter Pylori-Positive Subjects
  • Arnon Blum, Snait Tamir, Keren Mualem, Rotem Shelly Ben-Shushan, Lital Keinan-Boker, Maya Paritsky

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.